GSK work on malaria vaccine suffers setback

Work moves forward on GlaxoSmithKline malaria vaccine, though recent study results send some mixed signals
| 2 min read
LONDON—In its news release Nov. 9 about resultsfrom a large-scale Phase III trial of its RTS,S malaria vaccine,GlaxoSmithKline (GSK) led off with the fact that data show the "vaccinecandidate can help protect African infants against malaria" and infants vaccinatedwith RTS,S "had one-third fewer episodes of both clinical and severe malariaand had similar reactions to the injection."
To continue reading this article, subscribe for FREE toDrug Discovery News Logo

Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.

About the Author

Related Topics



Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Scientist weighing a laboratory sample using a four-decimal analytical balance in a quality control setting.
Learn the fundamental weighing principles and operational controls that support reliable sample preparation.
How new alternative methods are changing drug safety testing.
 Can animal testing be replaced? Discover how scientists are developing more human-relevant ways to predict drug toxicity earlier.
White laboratory mouse standing in a petri dish in a laboratory, illustrating a rodent model commonly used in scientific and preclinical studies.
Learn about common challenges and proper maintenance practices for catheterized rodent models.
Drug Discovery News December 2025 Issue
Latest IssueVolume 21 • Issue 4 • December 2025

December 2025

December 2025 Issue

Explore this issue